An observational study in Hepatocholangiocarcinoma, Fibrolamellar Carcinoma and Hepatic Epithelioid Hemangioendothelioma, sponsored by Federation Francophone de Cancerologie Digestive. Recruiting at 40 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-05.
Sponsored by Federation Francophone de Cancerologie Digestive · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Liver Neoplasms with a site in France — 16 open to participants now, 28 under way, 4 of them phase 3. Liver Neoplasms · France.
Among the 93 studies in Liver Neoplasms with a site in France, this one is the 17th largest by planned enrollment of the 26 observational ones that give a count, is one of 3 that started in 2024, is one of 26 observational ones, reaches primary completion later than 7 of the 27 other live ones, and was the 87th registered.
1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.
Browse Liver Neoplasms studies →16 of the 93 studies in Liver Neoplasms with a site in France are open now. Recruiting first, the newest first:
Mark C Burgmans, MD PhD · Sites in France, Netherlands
Ages 18+
University Hospital, Lille · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Ages 18–100
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 28 · Phase 3 21
First in 1999; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 200 across 344 observational studies indexed under Liver Neoplasms.
Median enrollment 129 across the 66 interventional studies, 303 across the 26 observational. Of the 60 that completed or were terminated, 22 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 93 have an industry lead sponsor. The 10 most frequent:
Federation Francophone de Cancerologie Digestive is the lead sponsor of 63 studies on the registry; 15 are open to participants now.
Federation Francophone de Cancerologie Digestive has 6 studies filed under Liver Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Liver Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03408665Centre Oscar LambretStereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer | 2026-12-01 |
| NCT02954094Target PharmaSolutions, Inc.A Longitudinal Observational Study of the Natural History and Management of Patients With HCC | 2027-02 |
| NCT04008797Eisai Inc.A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | 2027-03-31 |
| NCT06923761Grey Wolf TherapeuticsEMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) | 2027-04-30 |
| NCT05063565Boston Scientific CorporationTheraSphere With Durvalumab and Tremelimumab for HCC | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 93 studies in Liver Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.
The aim is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences.
In the health centers, patients were identified in two ways:
Patients with a diagnosis of rare primary hepatic cancers diagnosed on or after 01/01/2018 may be included, whether alive or deceased at the time of registration in the CAPRIH cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Description of the clinical, histological and radiological characteristics of various rare primary liver cancers
Description of the clinical, histological and radiological characteristics of various rare primary liver cancers
Time frame: up to 5 years from the date of diagnosis
Recurrence-free survival (for non-metastatic patients)
Time interval between the date of disease diagnosis and the date of locoregional and/or metastatic recurrence or death (all causes). Patients alive and without recurrence will be censored at the date of last news
Time frame: up to 5 years from diagnosis
Progression-free survival (for metastatic patients)
Time interval between the date of diagnosis of the disease and the date of radiological and/or clinical progression or death (all causes). Patients alive and progression-free will be censored at the date of last news.
Time frame: up to 5 years from diagnosis
Overall survival
Time interval between the date of diagnosis of the disease and the date of death (from all causes). Living patients will be censored at the date of last news.
Time frame: up to 5 years from diagnosis
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Feb 2026, 23 months after the start.
Of 132 non-industry observational studies under Liver Neoplasms, half reached primary completion within 114 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 172. This study's planned 23 months is below that.
Counting every sponsor, half of 160 studies reached it within 59 months; a quarter within 34 and three quarters within 172.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Federation Francophone de Cancerologie Digestive